Zydus Cadila has received the final approval from the USFDA to market Doxycycline Hyclate Delayed-Release Tablets USP (US RLD Doryx) in the strengths of 75 mg, 100 mg and 150 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad. This medication is used only to treat or prevent infections that are proven or
strongly suspected to be caused by susceptible bacteria.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
